The effects of indomethacin, a PG synthesis inhibitor, on the renal hemodynamic and diuretic responses to indanone were evaluated in 10 rats and 12 dogs. In anaesthetized rats, 50 mg/kg of indanone, an indanyloxyacetic acid diuretic, increased water excretion 20--30 times, sodium excretion 80--100 times, and potassium excretion 4 times, without marked changes in GFR and BP. Indomethacin pretreatment, 2 mg/kg, did not significantly reduce these responses. In vehicle pretreated dogs, urine flow, and sodium and potassium excretions increased 9,7 and 2 fold, respectively, after 4 mg/kg indanone. These responses were significantly diminished in dogs pretreated with 4 mg/kg indomethacin. Mean RBF was reduced 17% (P less than 0.02) after 10 min of indanone infusion (0.2 mg/kg/min). Indomethacin failed to alter this effect, suggesting the action of indanone differs from that of furosemide and ethacrynic acid, agents know to cause PG mediated renal vasodilation. The cyclooxygenase inhibitor did inhibit the diuretic response to indanone in these dogs. The dissimilar renal excretory response in the two species may reflect a more effective blockade by indomethacin of the tubular secretion of indanone in dogs than in rats. Alternatively, PGs may have different renal effects in the two species, or cyclooxygenase was inhibited to a greater extent in dogs than in rats.

Download full-text PDF

Source

Publication Analysis

Top Keywords

indanone dogs
12
dogs rats
12
renal effects
8
indanone
8
mg/kg indanone
8
dogs
7
renal
5
rats
5
indomethacin
5
effects indanone
4

Similar Publications

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.

Cell

November 2021

The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK. Electronic address:

Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative approach is to directly activate cholinergic receptors responsible for learning and memory. The M1-muscarinic acetylcholine (M1) receptor is the target of choice but has been hampered by adverse effects.

View Article and Find Full Text PDF

Long-acting injectable donepezil microspheres: Formulation development and evaluation.

J Control Release

December 2021

College of Pharmacy, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea. Electronic address:

Novel formulations of donepezil (DNP)-loaded microspheres based on a bio-degradable polymer of poly(lactic-co-glycolic acid) (PLGA) with a one-month duration of effect were developed, aimed at reducing dosing frequency and adverse effects and improving patient adherence. The spherical and monodispersed DNP-loaded microspheres were precisely fabricated by the Inventage Lab Precision Particle Fabrication method (IVL-PPFM®) based on micro-electromechanical systems (MEMS) and microfluidic technology. The types of polymers and end-groups, the drug/polymer ratio (DPR), and the routes of administration for DNP were studied to ensure an effective concentration and desired duration.

View Article and Find Full Text PDF

Development of an Amplicon-Based Next-Generation Sequencing Protocol to Identify Species and Other Trypanosomatids in Leishmaniasis Endemic Areas.

Microbiol Spectr

October 2021

Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.

Trypanosomatid infections are an important public health threat affecting many low-income countries across the tropics, particularly in the Americas. Trypanosomatids can infect many vertebrate, invertebrate, and plant species and play an important role as human pathogens. Among these clinically relevant pathogens are species from the genera and .

View Article and Find Full Text PDF

Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P) and 5 (S1P), is approved for the treatment of relapsing multiple sclerosis (MS) in multiple countries. Ozanimod profiling revealed a species difference in its potency for S1P in mouse, rat, and canine compared with that for human and monkey. Site-directed mutagenesis identified amino acid alanine at position 120 to be responsible for loss of activity for mouse, rat, and canine S1P, and mutation back to threonine as in human/monkey S1P restored activity.

View Article and Find Full Text PDF

α -Adrenoceptor agonists such as clonidine and dexmedetomidine are used as adjuvants to local anesthetics in regional anesthesia. Fadolmidine is an α -adrenoceptor agonist developed especially as a spinal analgesic. The current studies investigate the effects of intrathecally administered fadolmidine with a local anesthetic, bupivacaine, on antinociception and motor block in conscious rats and dogs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!